Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
I-Mab (NASDAQ:IMAB – Free Report) had its price objective lowered by Needham & Company LLC from $24.00 to $23.00 in a report published on Monday, Marketbeat.com reports. The firm currently has a buy rating on the stock. Several other brokerages have also recently issued reports on IMAB. HC Wainwright lowered their price target on shares […]
I-Mab (NASDAQ:IMAB – Free Report) had its target price decreased by HC Wainwright from $25.00 to $18.00 in a report issued on Friday morning, Marketbeat reports. HC Wainwright currently has a buy rating on the stock. Separately, Needham & Company LLC restated a buy rating and issued a $24.00 price objective on shares of I-Mab […]
Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...
I-Mab (NASDAQ:IMAB – Get Free Report) will be issuing its 06/30/2023 quarterly earnings data before the market opens on Thursday, August 17th. Analysts expect the company to announce earnings of $0.57 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link. I-Mab Trading Down 6.3 […]
Politan Capital won two seats on the board of monitoring-tech firm Masimo. Carlyle Group cut its stake in pharmaceuticals firm Vera.